Profund Advisors LLC Sells 960 Shares of Eli Lilly and Company (NYSE:LLY)

Profund Advisors LLC lessened its stake in shares of Eli Lilly and Company (NYSE:LLYGet Rating) by 6.1% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 14,881 shares of the company’s stock after selling 960 shares during the period. Profund Advisors LLC’s holdings in Eli Lilly and were worth $4,812,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Insight Inv LLC bought a new stake in shares of Eli Lilly and during the 2nd quarter worth about $26,000. Castle Wealth Management LLC bought a new stake in Eli Lilly and during the 2nd quarter valued at approximately $28,000. Horan Securities Inc. boosted its stake in Eli Lilly and by 96.0% during the 2nd quarter. Horan Securities Inc. now owns 98 shares of the company’s stock valued at $32,000 after purchasing an additional 48 shares during the period. Cypress Capital Management LLC WY boosted its stake in Eli Lilly and by 300.0% during the 2nd quarter. Cypress Capital Management LLC WY now owns 100 shares of the company’s stock valued at $32,000 after purchasing an additional 75 shares during the period. Finally, New Millennium Group LLC bought a new stake in shares of Eli Lilly and in the 2nd quarter worth approximately $34,000. Institutional investors own 82.13% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on LLY. Morgan Stanley dropped their target price on Eli Lilly and from $446.00 to $440.00 and set an “overweight” rating for the company in a report on Wednesday, December 14th. Guggenheim increased their target price on Eli Lilly and from $399.00 to $401.00 and gave the stock a “buy” rating in a report on Wednesday, December 7th. Cowen increased their target price on Eli Lilly and from $390.00 to $430.00 in a report on Monday, December 5th. Argus increased their target price on Eli Lilly and from $315.00 to $360.00 in a report on Friday, September 30th. Finally, StockNews.com started coverage on Eli Lilly and in a report on Wednesday, October 12th. They set a “buy” rating for the company. Two research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $384.11.

Eli Lilly and Trading Down 0.1 %

Shares of NYSE LLY traded down $0.50 during midday trading on Wednesday, hitting $345.89. The stock had a trading volume of 581,116 shares, compared to its average volume of 2,425,320. The company’s 50-day simple moving average is $361.80 and its 200 day simple moving average is $338.46. The firm has a market cap of $328.66 billion, a P/E ratio of 52.01, a price-to-earnings-growth ratio of 2.12 and a beta of 0.36. Eli Lilly and Company has a fifty-two week low of $231.87 and a fifty-two week high of $384.44. The company has a debt-to-equity ratio of 1.39, a current ratio of 1.13 and a quick ratio of 0.88.

Eli Lilly and (NYSE:LLYGet Rating) last released its earnings results on Tuesday, November 1st. The company reported $1.98 EPS for the quarter, beating the consensus estimate of $1.97 by $0.01. The company had revenue of $6.94 billion during the quarter, compared to analysts’ expectations of $6.91 billion. Eli Lilly and had a return on equity of 80.80% and a net margin of 20.63%. Research analysts anticipate that Eli Lilly and Company will post 7.77 EPS for the current year.

Eli Lilly and Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 10th. Shareholders of record on Wednesday, February 15th will be issued a dividend of $1.13 per share. The ex-dividend date is Tuesday, February 14th. This represents a $4.52 dividend on an annualized basis and a yield of 1.31%. This is a boost from Eli Lilly and’s previous quarterly dividend of $0.98. Eli Lilly and’s dividend payout ratio (DPR) is 58.86%.

Insider Transactions at Eli Lilly and

In related news, major shareholder Lilly Endowment Inc sold 49,089 shares of the stock in a transaction that occurred on Friday, December 2nd. The shares were sold at an average price of $372.88, for a total value of $18,304,306.32. Following the sale, the insider now directly owns 102,948,810 shares in the company, valued at approximately $38,387,552,272.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 49,089 shares of the stock in a transaction on Friday, December 2nd. The shares were sold at an average price of $372.88, for a total value of $18,304,306.32. Following the sale, the insider now directly owns 102,948,810 shares in the company, valued at $38,387,552,272.80. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, major shareholder Acquisition Corp Kearny purchased 29,992,668 shares of Eli Lilly and stock in a transaction dated Wednesday, November 30th. The shares were purchased at an average cost of $12.50 per share, for a total transaction of $374,908,350.00. Following the completion of the transaction, the insider now owns 100 shares of the company’s stock, valued at $1,250. The disclosure for this purchase can be found here. In the last ninety days, insiders sold 120,141 shares of company stock worth $44,151,279. 0.12% of the stock is currently owned by company insiders.

Eli Lilly and Profile

(Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Further Reading

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYGet Rating).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.